Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation

American Journal of Nephrology

Volumn 27, Issue 6, 2007, Pages 630-638

  Corna, Daniela ^a   Sangalli, Fabio ^a   Cattaneo, Dario ^a,b   Carrara, Fabiola ^a   Gaspari, Flavio ^a   Remuzzi, Andrea ^a   Zoja, Carla ^a   Benigni, Ariela ^a   Perico, Norberto ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Chronic kidney disease; Glomerular capillary size selective properties; Proteinuria; Renal hemodynamics; Renal mass ablation; Rosuvastatin

Indexed keywords

BETA 2 MICROGLOBULIN; FICOLL; ROSUVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SAFETY; FOLLOW UP; GLOMERULOPATHY; GLOMERULUS CAPILLARY; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION;

ANIMALS; CAPILLARIES; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY GLOMERULUS; PROTEINURIA; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 35549004107     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108359     Document Type: Article

References (46)

1. McCullough PA: Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 2004;3:591-600.
2. Basi S, Lewis JB: Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006;47:927-946.
3. Ruggenenti P, Remuzzi G: Angiotensin-converting enzyme inhibitor therapy for nondiabetic progressive renal disease. Curr Opin Nephrol Hypertens 1997;6:489-495.
4. Ruggenenti P: Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 2004;24:158-167.
5. Bos H, Henning RH, De Jong PE, De Zeew D, Navis G: Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition? Nephrol Dial Transplant 2002;17:793-797.
6. Keane WF: The role of lipids in renal disease: future challenges. Kidney Int 2000;75(suppl 92):S27-S31.
7. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262-F272.
8. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260-269.
9. Afzali B, Haydar AA, Vinen K, Goldsmith DJ: From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004;15:2161-2168.
10. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000;101:207-213.
11. Halcox JP, Deanfield JE: Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004;109(suppl 1):II42-II48.
12. Mason JC: The statins - therapeutic diversity in renal disease? Curr Opin Nephrol Hypertens 2005;14:17-24.
13. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tommasoni S, Abbate M, Remuzzi G: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002;61:1635-1645.
14. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Zanchi C, Abbate M, Remuzzi G: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898-2908.
15. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research. Endocrinologic and Metabolic Drugs Advisory Committee July 9, 2003 (available at http://www.fda.gov/ohrmsdockets/ ac/03/transcripts/3968T1.doc).
16. Deslypere JP, Delanghe J, Vermeulen A: Proteinuria as complication of simvastatin treatment. Lancet 1990;336:1453.
17. Van Zyl-Smit R, Firth JC, Duffield M, Ma rais AD: Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant 2004;19:3176-3179.
18. Wolfe SM: Dangers of rosuvastatin identified before and after FDA approval. Lancet 2004;363:2189-2190.
19. Agarwal R: Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 2004;15:2502-2503.
20. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG: Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102:52-60.
21. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004;15:2258-2265.
22. Verhulst A, D'Haese PC, De Broe ME: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004;15:2249-2257.
23. Olson JL, Hostetter TH, Rennke HG, Brenner BM, Venkatachalam MA: Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int 1982;22:112-126.
24. Vaziri ND, Liang K: Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome. Am J Nephrol 2004;24:606-613.
25. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995;6:257-263.
26. Jeansson M, Haraldsson B: Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes. J Am Soc Nephrol 2003;14:1756-1765.
27. Comper WD, Osicka TM, Jerums G: High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis 2003;41:336-342.
28. Galaske RG, Baldamus CA, Stolte H: Plasma protein handling in the rat kidney: micropuncture experiments in the acute heterologous phase of anti-GBM-nephritis. Pflügers Arch 1978;375:269-277.
29. Tojo A, Endou H: Intrarenal handling of proteins in rats using fractional micropuncture technique. Am J Physiol 1992;263:F601-F606.
30. Macconi D, Ghilardi M, Bonassi ME, Mohamed EI, Abbate M, Colombi F, Remuzzi G, Remuzzi A: Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol 2000;11:477-489.
31. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63:1094-1103.
32. Oliver JD 3rd, Anderson S, Troy JL, Brenner BM, Deen WH: Determination of glomerular size-selectivity in the normal rat with Ficoll. J Am Soc Nephrol 1992;3:214-228.
33. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G: Angiotensin-converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990;85:541-549.
34. Yoshioka T, Rennke HG, Salant DJ, Deen WM, Ichikawa I: Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: a study in early passive Heymann nephritis. Circ Res 1987;61:531-538.
35. Remuzzi A, Puntorieri S, Alfano M, Macconi D, Abbate M, Bertani T, Remuzzi G: Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. Lab Invest 1992;67:572-579.
36. Remuzzi A, Mohamed EI: Impact of reninangiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease. Exp Nephrol 1996;4(suppl 1):27-33.
37. Ellis S, Mellor H: Regulation of endocytic traffic by rho family GTPases. Trends Cell Biol 2000;10:85-88.
38. Somsel Rodman J, Wandinger-Ness A: Rab GTPases coordinate endocytosis. J Cell Sci 2000;113:183-192.
39. Liang K, Kim CH, Vaziri ND: HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 2005;288:F539-F544.
40. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, Bellosta S, Canadesi M, Rottoli D, Guerrini U, Brioschi M, Banfi C, Tremoli E, Remuzzi G, Sironi L: Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 2007;170:1165-1177.
41. Kim S, Kim CH, Vaziri ND: Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy. Am J Physiol 2005;288:E813-E817.
42. Moritomo Y, Hirano T, Ebara T, Kurokawa M, Naito H, Furusaka S, Nagano S: Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats. Nephron 1994;67:218-225.
43. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T: Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 1998;9:2027-2039.
44. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bierenger M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000;58:1420-1430.
45. Sarafidis PA, Kanaki AI, Lasaridis AN: Effects of statins on blood pressure: a review of the experimental and clinical evidence. Curr Vasc Pharmacol 2007;5:155-161.
46. Mangat S, Agarwal S, Rosendorff C: Do statins lower blood pressure? J Cardiovasc Pharmacol Ther 2007;12:112-123.